4/A 1 bzfrm4.txt U.S. SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940 [X] Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). ________________________________________________________________________________ 1. Name and Address of Reporting Person* BZ Group Holding Limited+ -------------------------------------------------------------------------------- (Last) (First) (Middle) Egglirain 24 -------------------------------------------------------------------------------- (Street) 8832 Wilen , Switzerland -------------------------------------------------------------------------------- (City) (State) (Zip) ________________________________________________________________________________ 2. Issuer Name and Ticker or Trading Symbol Tularik Inc. (TLRK) ________________________________________________________________________________ 3. IRS Identification Number of Reporting Person, if an Entity (Voluntary) ________________________________________________________________________________ 4. Statement for Month/Year July 2002 ________________________________________________________________________________ 5. If Amendment, Date of Original (Month/Year) February 2001 ________________________________________________________________________________ 6. Relationship of Reporting Person to Issuer (Check all applicable) [_] Director [X] 10% Owner [_] Officer (give title below) [_] Other (specify below) ________________________________________________________________________________ 7. Individual or Joint/Group Filing (Check applicable line) [_] Form filed by one Reporting Person [X] Form filed by more than one Reporting Person ________________________________________________________________________________ ================================================================================ Table I -- Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned ================================================================================
6. 4. 5. Owner- Securities Acquired (A) or Amount of ship 3. Disposed of (D) Securities Form: 7. Transaction (Instr. 3, 4 and 5) Beneficially Direct Nature of 2. Code ------------------------------- Owned at End (D) or Indirect 1. Transaction (Instr. 8) (A) of Month Indirect Beneficial Title of Security Date ------------ Amount or Price (Instr. 3 (I) Ownership (Instr. 3) (mm/dd/yy) Code V (D) and 4) (Instr.4) (Instr. 4) ------------------------------------------------------------------------------------------------------------------------------------ Common Stock 07/30/02 J(1) 11,358,238 D N/A 800,000 D ------------------------------------------------------------------------------------------------------------------------------------ Common Stock 06/28/02 S(2) 1,200,000 D USD 9.00 0 ------------------------------------------------------------------------------------------------------------------------------------ Common Stock 06/28/02 P(2) 1,200,000 A USD 9.00 11,358,238 D ------------------------------------------------------------------------------------------------------------------------------------
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the Form is filed by more than one Reporting Person, see Instruction 4(b)(v). + BZ Group Holding Limited is reporting on behalf of itself, Pharma Vision AG and Spezialitaten Vision AG. FORM 4 (continued) Table II -- Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) ================================================================================
10. 9. Owner- Number ship of Form 2. Deriv- of Conver- 5. 7. ative Deriv- 11. sion Number of Title and Amount Secur- ative Nature or Derivative 6. of Underlying 8. ities Secur- of Exer- 4. Securities Date Securities Price Bene- ity: In- cise 3. Trans- Acquired (A) Exercisable and (Instr. 3 and 4) of ficially Direct direct Price Trans- action or Disposed Expiration Date ---------------- Deriv- Owned (D) or Bene- 1. of action Code of(D) (Month/Day/Year) Amount ative at End In- ficial Title of Deriv- Date (Instr. (Instr. 3, ---------------- or Secur- of direct Owner- Derivative ative (Month/ 8) 4 and 5) Date Expira- Number ity Month (I) ship Security Secur- Day/ ------ ------------ Exer- tion of (Instr. (Instr. (Instr. (Instr. (Instr. 3) ity Year) Code V (A) (D) cisable Date Title Shares 5) 4) 4) 4) ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ ====================================================================================================================================
Explanation of Responses: See Attachment A for footnotes. BZ Group Holding Limited /s/ Kurt Schiltknecht 8/9/02 --------------------------------------------- **Signature of Reporting person Date By: Kurt Schiltknecht, Director Pharma Vision AG /s/ Martin Ebner 8/9/02 --------------------------------------------- **Signature of Reporting person Date By: Martin Ebner, Chairman Spezialitaten Vision AG /s/ Martin Ebner 8/9/02 --------------------------------------------- **Signature of Reporting person Date By: Martin Ebner, Chairman ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. Attachment A Explanation of Responses (1) On July 30, 2002, BZ Group Holding Limited sold all of its holdings of registered shares of Pharma Vision AG and Spezialitaten Vision AG to Cantonal Bank of Zurich pursuant to a Purchase Agreement between BZ Group Holding Limited and Cantonal Bank of Zurich. Accordingly, as of July 30, 2002, BZ Group Holding Limited had no beneficial ownership of any Common Stock of Tularik Inc. (the "Company"), except that BZ Group Holding Limited directly held 800,000 shares of the Company's Common Stock, representing approximately 1.6% of Common Stock outstanding. Therefore, as of July 30, 2002, BZ Group Holding Limited ceased to be the beneficial owner of more than ten percent of the Company's Common Stock. The principal business address of Spezialitaten Vision AG is Egglirain 24, 8832 Wilen, Switzerland. The principal business address of Pharma Vision AG is Spielhof 3, 8750 Glarus, Switzerland. (2) On June 28, 2002, Spezialitaten Vision AG sold its 1,200,000 shares of the Company's Common Stock previously reported on Form 4 to Pharma Vision AG.